Image
Interactive Exchangeā„¢

Multidimensional Issues in Type 2 Diabetes

Looking Beyond Hemoglobin A1c

Meeting Slides

Suggested Readings

Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).

Cannon CP, McGuire DK, Pratley R, et al. Am Heart J. 2018;206:11-23.

Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.

DeFronzo RA, Norton L, Abdul-Ghani M. Nat Rev Nephrol. 2017;13(1):11-26.

Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention.

Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Lancet. 2013;382(9889):339-352.

SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.

Inzucchi SE, Zinman B, Wanner C, et al. Diab Vasc Dis Res. 2015;12(2):90-100.

Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic.

King RJ, Grant PJ. Herz. 2016;41(3):184-192.

Diabetes mellitus and heart failure.

Lehrke M, Marx N. Am J Cardiol. 2017; 120(suppl 1):S37-S47.

Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups.

Mahaffey KW, Jardine MJ, Bompoint S, et al. Circulation. 2019;140(9):739-750.

Dapagliflozin in patients with heart failure and reduced ejection fraction.

McMurray JJV, Solomon SD, Inzucchi SE, et al. N Engl J Med. 2019. [Epub ahead of print]

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.

Mosenzon O, Wiviott SD, Cahn A, et al. Lancet Diabetes Endocrinol. 2019;7(8):606-617.

Canagliflozin and cardiovascular and renal events in type 2 diabetes.

Neal B, Perkovic V, Mahaffey KW, et al. N Engl J Med. 2017;377(7):644-657.

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.

Perkovic V, Jardine MJ, Neal B, et al. N Engl J Med. 2019;380(24):2295-2306.

Diabetic kidney disease.

Thomas MC, Brownlee M, Susztak K, et al. Nat Rev Dis Primers. 2015;1:15018.

Diabetic kidney disease: pathophysiology and therapeutic targets.

Toth-Manikowski S, Atta MG. J Diabetes Res. 2015;2015:697010.

SGLT2 inhibition in the diabetic kidney—from mechanisms to clinical outcome.

van Bommel EJ, Muskiet MH, Tonneijck L, et al. Clin J Am Soc Nephrol. 2017;12(4):700-710.

Empagliflozin and progression of kidney disease in type 2 diabetes.

Wanner C, Inzucchi SE, Lachin JM, et al. N Engl J Med. 2016;375(4):323-334.

Dapagliflozin and cardiovascular outcomes in type 2 diabetes.

Wiviott SD, Raz I, Bonaca MP, et al. N Engl J Med. 2019;380(4):347-357.

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

Zelniker TA, Wiviott SD, Raz I, et al. Lancet. 2019;393(10166):31-39.

Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.

Zinman B, Wanner C, Lachin JM, et al. N Engl J Med. 2015;373(22):2117-2128.

Interactive Presentation

Connecting T2DM Pathophysiology, Comorbidities, and SGLT2 Inhibitors

Presented by Derek LeRoith, MD, PhD


Activity
Multidimensional Issues in Type 2 Diabetes

Debates and Discussions Around Cardiovascular and Renal Outcomes

Activity
Multidimensional Outcomes in Type 2 Diabetes

Looking Beyond Hemoglobin A1c

Relevant Resources

Incretin-Based Therapies for Type 2 Diabetes

Mechanism-Based Strategies to Achieve Patient-Centered Care

Insulin Replacement Therapy for Type 2 Diabetes

Patient-Centered Management of Hyperglycemia in Primary Care

Improving Outcomes in Type 2 Diabetes

Integrating GLP-1 Receptor Agonists Into Multimodal Treatment Regimens

A Focus on Bipolar Depression

Overcoming Diagnostic Barriers and Optimizing Long-Term Patient Outcomes

Clinical Issues in Type 2 Diabetes

Discussions and Debates Around GLP-1 Receptor Agonists

Clinical Issues in Type 2 Diabetes

Evolving Roles of GLP-1 Receptor Agonists

Improving Outcomes for Women with Type 2 Diabetes

Individualizing Evidence-Based Care

Noninsulin Approaches to Managing Type 2 Diabetes

Best Practices in Combination Therapy

Hitting the Target in Type 2 Diabetes

Evolving Approaches to Insulin Based Therapy

Improving Outcomes in Congenital and Acquired Lipodystrophy

Best Practices in Diagnosis and Management

Clinical Updates in Type 2 Diabetes

New Strategies for Insulin Replacement Therapy

Clinical Issues in Type 2 Diabetes

Consensus and Controversies Around Intensifying Noninsulin Therapy

How Low Do You Go?

Clinical Updates in LDL-C Management

Incretin-Based Therapies For Type 2 Diabetes

Improving Comprehensive Patient Care

Clinical Updates in Type 2 Diabetes

An Evolving Role for Combinations of Injectable Antihyperglycemic Therapies

Raising the Bar by Lowering the Target

Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management

Injecting New Ideas into Managing Type 2 Diabetes

Evolving Roles of GLP-1 Receptor Agonists

GLP-1 Receptors Agonists in Type 2 Diabetes

Mechanistic Insights and Evolving Treatment Options

Pharmaceutical Economics and LDL-C Management

Implications for PCSK9 Inhibitors in Clinical Practice